BIOSPECTATOR: RudaCure, 'Rac1 inhibitor' 干眼症治疗药 — "Domestic Phase 1 trial in H2"
CEO Yongho Kim of RudaCure stated, "Our 干眼症治疗药 candidate, the Rac1 inhibitor 'RCI001 (8-oxo-2'-deoxyguanosine),' showed significant 角膜损伤恢复 and increased 泪液分泎 compared to the control drug from day 5 of administration in 小鼠模型 studies, with no 副作用 observed even after 5–6 weeks of administration," adding, "We expect it to fulfill the 未满足的医疗需求 of existing drugs that required long-term administration."
Additionally, RudaCure is preparing a pre-IND meeting with 美国 Food and Drug Administration (FDA) for Phase 2 临床试验, targeting IND submission by the end of this year or early next year.
RudaCure was founded in 2018 by Professor Yongho Kim of 嘉泉大学医学院 and raised KRW 6 billion through Series A in May. In addition to RCI001, RudaCure is currently conducting 临床前 research on TRPV1 antagonist 'RCI002' as a 神经性疼痛 treatment.
